WALTHAM,
Mass., Jan. 2, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical
company developing an innovative pipeline of cancer therapies,
today announced that Michael A.
Metzger, Chief Executive Officer of Syndax, will present at
the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 5:15 p.m. PT/ 8:15 p.m.
ET.
A live webcast of the fireside chat can be accessed from the
Investor section of the Company's website at www.syndax.com, where
a replay of the event will also be available for a limited
time.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include revumenib, a highly
selective inhibitor of the menin–KMT2A binding interaction, and
axatilimab, a monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor. For more information, please
visit www.syndax.com or follow the Company on
Twitter and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-42nd-annual-jp-morgan-healthcare-conference-302024252.html
SOURCE Syndax Pharmaceuticals, Inc.